Ophthalmic formulations and methods of use
US12311004B2 · kind B2 · utility
0Cited by
0References
12Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Sep 26, 2024 |
| Grant date | May 27, 2025 |
| Priority date | — |
| Expiry date | Sep 26, 2044 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2300/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Feline herpesvirus (FHV-1) is a highly contagious virus affecting domestic and wild felines and is the leading cause of corneal disease and conjunctivitis in cats. Thus, provided herein is topical ophthalmic formulation for treating FHV-1, comprising L-lysine and a second therapeutic agent, such as osha root (e.g., ligustilide). The formulation enables direct and concentrated delivery to the ocular surface, which is believed to enhance efficacy in treating herpesvirus infections. This innovative approach improves treatment outcomes by targeting the virus more effectively at the site of infection.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.